Fritextsökning
Innehållstyper
-
Medicult disclaims Swedish offer
The Norwegian company Medicult's Board is highly sceptical to the yesterday announced Vitrolife offer.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...
-
Karin Meyer lämnar PCG
Karin Meyer går till nytt jobb.
-
Hormones make children fat
A new Danish million project will define the connection between hormons and obesity amongst children.
-
Top modern lab to Sahlgrenska
The Sahlgrenska Science Park will soon open the doors to a brand new wet laboratory.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
-
Startskott för blödarstudie
Nu doseras första patienten i fas II/III-studien med Sobis och Biogenidecs läkemedelskandidat mot blödarsjuka.
-
Martin Bergö: "The Idea is the Thing"
Martin Bergö, 38, goes wherever ideas take him - it's a process that has led to, and resulted from, plenty of unexpected results. Those ideas have been recogniz...
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
-
Annika Garnås, LAB
Why are you going to Scanlab+Biotech Forum?
-
Bio engineering breakthrough in Denmark
Brand new research makes BioGasol's cellulosic ethanol process even more competitive.
-
Biotech goes white and bright
White biotech could become Denmark's next blossoming business area.
-
Pronova Biopharma grows
Recently, Norway's Pronova Biopharma announced the creation of new jobs in Denmark
-
Presenterar data från två kliniska studier
Sobi och partnern Biogen visar upp nya resultat på kongress i Kanada.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Biovitrum får orphan drug-status i EU
Färre behandlingstillfällen för blödarsjuka är i sikte med Swedish Orphan Biovitrums läkemedelskandidat. Nu kan läkemedlet nå den europeiska marknaden fortare.
-
Density meters with six-digit precision
The new instruments from Krüss Optronic offer high sensitivity for density measurements.
-
Swetox får 30 miljoner
Ska forska på hormonstörande ämnen.
-
Han blir kommersiell chef på Sobi
Hemofililedare tar ansvar över kommande kommersialisering.
-
Almost 150 will leave Coloplast
The Danish medtech company Coloplast negotiates headcount reductions, with a total number of almost 150 employees.
-
Fusion between pharma giants?
It is rumoured that a fusion between Pfizer and Wyeth is in the process of happening.
-
Danisco first with green emulsifier
A new sustainable emulsifier from Danisco meets the increasing consumer demand for ethically correct consumer goods.
-
Schizophrenia and bipolar disorder are relatives
Schizophrenia and bipolar disorder have the same genetic causes, according to a study from Karolinska Institutet.